JP2013198737A - 生体適合性高分子を用いた移植用材料 - Google Patents
生体適合性高分子を用いた移植用材料 Download PDFInfo
- Publication number
- JP2013198737A JP2013198737A JP2013058334A JP2013058334A JP2013198737A JP 2013198737 A JP2013198737 A JP 2013198737A JP 2013058334 A JP2013058334 A JP 2013058334A JP 2013058334 A JP2013058334 A JP 2013058334A JP 2013198737 A JP2013198737 A JP 2013198737A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- derivative film
- epoxide derivative
- group
- epoxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title description 3
- 229920000249 biocompatible polymer Polymers 0.000 title 1
- 238000002513 implantation Methods 0.000 title 1
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 97
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 97
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 65
- 229920000642 polymer Polymers 0.000 claims abstract description 39
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 19
- 150000002118 epoxides Chemical class 0.000 claims abstract description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- -1 hyaluronic acid epoxide Chemical class 0.000 claims description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 38
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 12
- 229940014041 hyaluronate Drugs 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 230000002138 osteoinductive effect Effects 0.000 claims description 9
- 229920001451 polypropylene glycol Polymers 0.000 claims description 9
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 230000008929 regeneration Effects 0.000 claims description 7
- 238000011069 regeneration method Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000000783 alginic acid Substances 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 229960001126 alginic acid Drugs 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 150000004781 alginic acids Chemical class 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 229960005188 collagen Drugs 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 229940014259 gelatin Drugs 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- HNRMPXKDFBEGFZ-UHFFFAOYSA-N ethyl trimethyl methane Natural products CCC(C)(C)C HNRMPXKDFBEGFZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- PGMKGZOHRBZSSQ-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethenoxymethyl]oxirane Chemical group C1OC1COC=COCC1CO1 PGMKGZOHRBZSSQ-UHFFFAOYSA-N 0.000 claims description 3
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 239000005445 natural material Substances 0.000 claims description 3
- 229920000223 polyglycerol Polymers 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 claims description 2
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 claims description 2
- HDPLHDGYGLENEI-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COC(C)COCC1CO1 HDPLHDGYGLENEI-UHFFFAOYSA-N 0.000 claims description 2
- WTYYGFLRBWMFRY-UHFFFAOYSA-N 2-[6-(oxiran-2-ylmethoxy)hexoxymethyl]oxirane Chemical compound C1OC1COCCCCCCOCC1CO1 WTYYGFLRBWMFRY-UHFFFAOYSA-N 0.000 claims description 2
- KUAUJXBLDYVELT-UHFFFAOYSA-N 2-[[2,2-dimethyl-3-(oxiran-2-ylmethoxy)propoxy]methyl]oxirane Chemical compound C1OC1COCC(C)(C)COCC1CO1 KUAUJXBLDYVELT-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229920000288 Keratan sulfate Polymers 0.000 claims description 2
- 102000007547 Laminin Human genes 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 108090000054 Syndecan-2 Proteins 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 2
- 229920001748 polybutylene Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims 1
- HPQIRFXIDGVWBA-UHFFFAOYSA-N 2-[13,17,18,21-tetrahydroxy-7-(hydroxymethyl)-2,10,14-trioxo-5-(3,4,5-trihydroxybenzoyl)oxy-3,6,9,15-tetraoxatetracyclo[10.7.1.14,8.016,20]henicosa-1(19),16(20),17-trien-11-yl]acetic acid Chemical compound OC1C2OC(=O)C(C3=4)=CC(O)=C(O)C=4OC(=O)C(O)C3C(CC(O)=O)C(=O)OC1C(CO)OC2OC(=O)C1=CC(O)=C(O)C(O)=C1 HPQIRFXIDGVWBA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 208000031737 Tissue Adhesions Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000010478 bone regeneration Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229920006254 polymer film Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000181 anti-adherent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 244000265736 Nelumbo pentapetala Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 235000011442 Prunus x yedoensis Nutrition 0.000 description 1
- 241000220307 Prunus yedoensis Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940074731 ophthalmologic surgical aids Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L101/00—Compositions of unspecified macromolecular compounds
- C08L101/02—Compositions of unspecified macromolecular compounds characterised by the presence of specified groups, e.g. terminal or pendant functional groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Manufacturing & Machinery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polyethers (AREA)
Abstract
【解決手段】ヒドロキシ(−OH)末端基を含む高分子を含有してなることを特徴とするヒアルロン酸エポキシド誘導体フィルム。
【選択図】図1
Description
実施例1〜4:ヒアルロン酸と混合して使用可能な高分子の架橋形成有無
この実験において、ヒアルロン酸と混合して使用可能な高分子が架橋されてエーテル共有結合を形成するか否かを判断するために、1重量%のヒアルロン酸、アルギン酸、ジェラチン、コラーゲンをそれぞれ1重量%のヒアルロン酸溶液と50/50にて混合し、ポリエチレンオキシドを5重量%添加した後、ここにそれぞれのエポキシド架橋剤(1,4−ブタンジオールジグリシジルエーテル、ポリエチレングリコールジグリシジルエーテル、ポリプロピレンジグリシジルエーテル、ネオペンチルジグリシジルエーテル)を混合された高分子の繰り返し単位100重量部に対して5重量部の割合で添加して12時間室温において架橋反応を行った後、固形物を取り出して脱イオン水中に1時間保管した。固形物が脱イオン水に溶解するか否かを確認して架橋形成の有無を判断した。
この実験において、ヒドロキシ末端基を含む高分子としてポリプロピレンオキシドを用いた。0.25NNaOHに10重量%のヒアルロン酸と30重量%のポリプロピレンオキシドとを混合した溶液をそれぞれ3つの反応器に用意した。前記溶液のヒアルロン酸100重量部に対してポリエチレングリコールジグリシジルエーテルをそれぞれ5重量部、10重量部、25重量部の割合にて添加した。室温下で24時間反応させた後、四角皿にとって均一に広げた後、12時間かけて室温下で乾燥して1次フィルムを製造した。1次フィルムを精製水により洗浄して非反応物及びポリプロピレンオキシドを除去した後にエタノールに沈殿し、且つ、収縮して2次フィルムを製造した。2次フィルムを精製水により再膨潤し、且つ、乾燥して最終的な誘導体フィルムを製造した。本発明の実験を行うために製造された誘導体フィルムを、架橋剤の割合に応じて、実験群1(5重量部)、実験群2(10重量部)、実験群3(25重量部)と命名した。
10重量%のヒアルロン酸を0.25NNaOHに溶かしてヒアルロン酸溶液を用意した。前記溶液のヒアルロン酸100重量部に対してポリエチレングリコールジグリシジルエーテルを25重量部の割合にて添加した後、室温下で24時間反応させた。前記溶液を四角皿にとって均一に広げた後、12時間かけて室温下で乾燥して1次フィルムを製造し、精製水により洗浄して非反応物を除去した。水和された誘導体をエタノールに沈殿して収縮させて2次フィルムを製造した後、精製水により再膨潤し、且つ、乾燥して最終的な誘導体フィルムを製造した。前記比較例1に従い製造された誘導体フィルムは実験群4と命名した。
試験例1:ヒドロキシ末端基を含む高分子の含有有無によるフィルム形状の比較
ヒドロキシ末端基を含む高分子フィルムの均一性を確認するために、実施例5及び比較例1に従いそれぞれ製造された1次フィルムの形状を写真により比較した。
1重量%のヒアルロン酸を脱イオン水に溶解してヒアルロン酸溶液を製造し、10重量%のヒドロキシ末端基を含む高分子を脱イオン水に溶解して溶液を製造した。製造された溶液をそれぞれ四角皿にとって室温下で12時間かけて乾燥してヒアルロン酸フィルム及びヒドロキシ末端基を含む高分子フィルムを製造した。ATR−IRを用いて、前記製造されたヒアルロン酸フィルム、ヒドロキシ末端基を含む高分子フィルム、実験群3及び実験群4の構造を分析した。
実施例5に従い製造された実験群1、2、3と、癒着防止剤(商品名:インターシード、米国のJ&J社製、比較群1)及び骨誘導再生膜(商品名:バイオガイド、スイスのガイストリッヒ・ファーマ社製、比較例2)の物理的強度値をそれぞれ比較・分析した。測定のために、試料を3cm×1cmに切り出して万能材料試験機(米国のインストロン社製)のグリップに載せた後、10mm/分の速度で引っ張りながら材料にかかる力を測定した。
実施例5の製造中に水和されたヒアルロン酸誘導体をエタノールにより処理した試料と処理しなかった試料の物理的強度を比較するために、実験群1、2、3と、実施例5の製造中に水和されたヒアルロン酸誘導体をエタノールにより沈殿せずに乾燥して製造した試料をそれぞれ用意した。それぞれの試料を実施例5の方法と同様にして用意して物理的強度を測定した。
実施例5に従い製造された試料の生体内残留期間を評価するために、動物実験を行った。実験動物としては、8週齢のスプラーグ−ドーリー(Sprague-Dawley)系ラットを用いた。麻酔剤をラットの下腹部に注射して麻酔を行い、背部に5mm×10mmのサイズの試片をそれぞれ移植し、2週目、4週目、12週目に組織学的分析(ヘマトキシリン・エオシン染色)により試片の残留有無を評価した。
実施例5に従い製造された試料の組織癒着防止能を評価するために、動物モデル(スプラーグ−ドーリー系ラット)を用いた。麻酔剤をラットの下腹部に注射して麻酔を行った。麻酔されたラットの腹部を切開し、腹膜の表皮部分に1cm×2cmのサイズの傷を骨バーを用いて付け、この傷と当接している盲腸に表皮が僅かに剥がれる程度に傷を付けた。傷と傷との間にいかなる癒着防止剤も使用しなかった対照群と、比較群1(インターシード)及び実施例5に従い製造された実験群1、2及び3の組織癒着を比較・観察した。各試料は、2cm×3cmのサイズに切って使用した。組織癒着度に応じて、4段階(0、1、2、3、数字が大きいほど癒着が激しい)の癒着評価システムを用いてその成績を合算し、平均を取った(A. A. Luciano, et al.,"Evaluation of commonly used adjuvants in the prevention of postoperativeadhesions", Am. J. Obstet. Gynecol.146, 88-92 (1983))。
実施例5に従い製造された実験群3の骨再生効果を確認するために、8週齢のスプラーグ−ドーリー系ラットを動物モデルとして使用した。実験動物を麻酔した後、額部分の中央の皮膚を約4cm切開した後、骨膜を切開して横に退けた状態で脳硬膜と頭蓋正中部を通る血管の損傷に注意しながら、直径8mmの歯科用ドリルを用いて臨界寸法欠損である直径8mmのサイズ[J. P Schmitz et al., Clin.Orthop. Relat. Res., 205, 299(1986)]の欠損部を形成した後、実験群3及び比較群2をΦ12mmの円形に切り取って欠損部位を覆い、骨膜と皮膚をそれぞれ縫合した。なお、骨欠損部にいかなる処理もせずに縫合した対照群についても実験を行った。12週間飼育した後、動物を犠牲にして骨欠損部を採取し、マイクロCT、軟X線により骨再生効果を評価した。
Claims (12)
- ヒドロキシ(−OH)末端基を含む高分子を含有してなることを特徴とするヒアルロン酸エポキシド誘導体フィルム。
- 前記ヒアルロン酸誘導体フィルムのヒアルロン酸は50〜90重量%であり、前記ヒドロキシ(−OH)末端基を含む高分子は10〜50重量%であることを特徴とする請求項1に記載のヒアルロン酸エポキシド誘導体フィルム。
- 前記ヒアルロン酸エポキシド誘導体フィルムの架橋密度が1mol%〜100mol%であることを特徴とする請求項1に記載のヒアルロン酸エポキシド誘導体フィルム。
- 前記ヒドロキシ(−OH)末端基を含む高分子は、ポリエチレンオキシド、ポリビニルアルコール、ポリプロピレンオキシド、ポリエチレンオキシド−ポリプロピレンオキシド共重合体、ポリエチレンオキシド−ポリ乳酸共重合体、ポリエチレンオキシド−ポリ乳酸グリコール酸共重合体、ポリエチレンオキシド−ポリカプロラクトン共重合体、ポリブチレンオキシド、ポリオキシエチレンアルキルエーテル類、ポリオキシ−エチレンひまし油誘導体類、ポリオキシエチレンソルビタン脂肪酸エステル類及びポリオキシエチレンステアレート類よりなる群から選ばれるいずれか1種以上であることを特徴とする請求項1に記載のヒアルロン酸エポキシド誘導体フィルム。
- 前記ヒアルロン酸エポキシド誘導体は、ヒアルロン酸又はヒアルロン酸塩単独、あるいは、ヒアルロン酸またはヒアルロン酸塩、及びヒアルロン酸とエーテル共有結合を形成しうる高分子とともにエポキシド架橋剤によって反応して製造されることを特徴とする請求項1に記載のヒアルロン酸エポキシド誘導体フィルム。
- 前記ヒアルロン酸塩は、ヒアルロン酸ナトリウム、ヒアルロン酸カリウム、ヒアルロン酸カルシウム、ヒアルロン酸マグネシウム、ヒアルロン酸亜鉛、ヒアルロン酸コバルト及びヒアルロン酸テトラブチルアンモニウムよりなる群から選ばれるいずれか1種以上であることを特徴とする請求項5に記載のヒアルロン酸エポキシド誘導体フィルム。
- 前記ヒアルロン酸とエーテル共有結合を形成しうる高分子は、ヒアルロン酸、コラーゲン、アルギン酸、ヘパリン、ジェラチン、エラスチン、フィブリン、ラミニン、フィブロネクチン、プロテオグリカン、ヘパランサルフェート、硫酸コンドロイチン、デルマタン硫酸及びケラタン硫酸よりなる群から選ばれるいずれか1種以上であることを特徴とする請求項5に記載のヒアルロン酸エポキシド誘導体フィルム。
- 前記エポキシド架橋剤は、ポリエチレングリコールジグリシジルエーテル、1,4−ブタンジオールジグリシジルエーテル、エチレングリコールジグリシジルエーテル、1,6−ヘキサンジオールジグリシジルエーテル、プロピレングリコールジグリシジルエーテル、ポリプロピレングリコールジグリシジルエーテル、ポリテトラメチレングリコールジグリシジルエーテル、ネオペンチルグリコールジグリシジルエーテル、ポリグリセロールポリグリシジルエーテル、ジグリセロールポリグリシジルエーテル、グリセロールポリグリシジルエーテル、トリメチルプロパンポリグリシジルエーテル、1,2−(ビス(2,3−エポキシプロポキシ)エチレン、ペンタエリスリトールポリグリシジルエーテル及びソルビトールポリグリシジルエーテルよりなる群から選ばれるいずれか1種以上であることを特徴とする請求項5に記載のヒアルロン酸エポキシド誘導体フィルム。
- 前記ヒアルロン酸の繰り返し単位100重量部に対して前記架橋剤1〜100重量部を架橋反応させることを特徴とする請求項5に記載のエポキシド誘導体エポキシド誘導体フィルム。
- 前記ヒアルロン酸エポキシド誘導体フィルムが、精製後に有機溶媒に沈殿して製造されたものであることを特徴とする請求項1に記載のヒアルロン酸エポキシド誘導体フィルム
- 前記ヒアルロン酸エポキシド誘導体フィルムは、癒着防止剤または骨誘導再生膜として用いられることを特徴とする請求項1に記載のヒアルロン酸エポキシド誘導体フィルム
- 抗菌及び抗炎症天然物質をさらに含むことを特徴とする請求項11に記載のヒアルロン酸エポキシド誘導体フィルム。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120030540A KR101240518B1 (ko) | 2012-03-26 | 2012-03-26 | 생체 적합성 고분자를 이용한 이식용 재료 |
KR10-2012-0030540 | 2012-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013198737A true JP2013198737A (ja) | 2013-10-03 |
JP5934132B2 JP5934132B2 (ja) | 2016-06-15 |
Family
ID=47913323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013058334A Expired - Fee Related JP5934132B2 (ja) | 2012-03-26 | 2013-03-21 | 生体適合性高分子を用いた移植用材料 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8822551B2 (ja) |
EP (1) | EP2644623B1 (ja) |
JP (1) | JP5934132B2 (ja) |
KR (1) | KR101240518B1 (ja) |
CN (1) | CN103360633B (ja) |
ES (1) | ES2621280T3 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102093660B1 (ko) * | 2019-07-08 | 2020-03-26 | (주)리젠바이오참 | 온도감응형 조직유착 방지용 하이드로겔 조성물 및 그 제조방법 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101649792B1 (ko) * | 2014-07-16 | 2016-08-22 | 주식회사 제네웰 | 비압박 지혈용 고분자 폼 제조용 조성물, 이를 이용한 비압박 지혈용 고분자 폼의 제조방법 및 비압박 지혈 팩킹용 고분자 폼 |
CZ309295B6 (cs) | 2015-03-09 | 2022-08-10 | Contipro A.S. | Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití |
RU2629841C1 (ru) * | 2016-07-26 | 2017-09-04 | Общество с ограниченной ответственностью "Линтекс" | Способ получения противоспаечного пленочного материала на основе карбоксиметилцеллюлозы |
KR20180027126A (ko) * | 2016-09-06 | 2018-03-14 | (주)한국비엠아이 | 가교화 히알루론산 유도체 매트릭스가 포함된 지혈 조성물 |
CN107880282B (zh) * | 2016-12-29 | 2020-09-29 | 北京键凯科技股份有限公司 | 一种注射用多元甘醇环氧衍生物交联的透明质酸钠凝胶及其制备方法 |
WO2018164358A1 (ko) | 2017-03-07 | 2018-09-13 | (주)진우바이오 | 히알루론산염 필름의 제조방법 및 이로부터 제조된 히알루론산염 필름 |
WO2019001472A1 (zh) * | 2017-06-28 | 2019-01-03 | 北京键凯科技股份有限公司 | 分枝型多元甘醇环氧衍生物交联透明质酸钠凝胶及其制备和应用 |
CN109010912B (zh) * | 2018-09-27 | 2021-05-25 | 福建拓烯新材料科技有限公司 | 一种改性的玻尿酸可注射填充材料及其制备方法 |
CN112472672B (zh) * | 2020-11-30 | 2022-01-25 | 西安交通大学 | 一种多肽-多糖接枝共聚物基铂类纳米前药及制备方法和应用 |
CN115838478B (zh) * | 2022-01-14 | 2023-09-05 | 天津键凯科技有限公司 | 一种透明质酸衍生物或其盐及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07102002A (ja) * | 1993-09-30 | 1995-04-18 | Gunze Ltd | 架橋ヒアルロン酸及びこれらの複合材料 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500676A (en) | 1983-12-15 | 1985-02-19 | Biomatrix, Inc. | Hyaluronate modified polymeric articles |
US4716224A (en) | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
SE442820B (sv) | 1984-06-08 | 1986-02-03 | Pharmacia Ab | Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut |
SE456346B (sv) | 1984-07-23 | 1988-09-26 | Pharmacia Ab | Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning |
US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
SE452469B (sv) | 1986-06-18 | 1987-11-30 | Pharmacia Ab | Material bestaende av en tverbunden karboxylgrupphaltig polysackarid och forfarande vid framstellning av detsamma |
US5827937A (en) | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
GB9902652D0 (en) | 1999-02-05 | 1999-03-31 | Fermentech Med Ltd | Process |
KR100721752B1 (ko) | 2000-01-24 | 2007-05-25 | 쿠라레 메디카루 가부시키가이샤 | 수팽윤성 고분자 겔 및 그 제조법 |
CN1774272A (zh) * | 2000-12-07 | 2006-05-17 | 株式会社日本组织工程 | 组织再生用基材、移植用材料及其制备方法 |
AU2003901834A0 (en) * | 2003-04-17 | 2003-05-01 | Clearcoll Pty Ltd | Cross-linked polysaccharide compositions |
AU2004277416A1 (en) * | 2003-09-30 | 2005-04-14 | Synthes Gmbh | Antimicrobial hyaluronic acid coatings for orthopedic implants |
KR101250846B1 (ko) * | 2005-07-04 | 2013-04-05 | 주식회사 엘지생명과학 | 히알루론산 가교물의 제조방법 |
KR20090012439A (ko) | 2007-07-30 | 2009-02-04 | 주식회사 핸슨바이오텍 | 기관 유착 방지 특성을 갖는 히알루론산 및카르복시메칠셀룰로즈 복합체 유도체 필름 및 겔 및 그제조방법 |
ITRM20080636A1 (it) * | 2008-11-28 | 2010-05-29 | Univ Palermo | Procedimento per la produzione di derivati funzionalizzati dell acido ialuronico e relativi idrogeli. |
KR101180286B1 (ko) | 2009-06-10 | 2012-09-14 | 가톨릭대학교 산학협력단 | 히알루론산 에폭사이드 유도체 하이드로겔을 포함하는 유착방지제 및 이의 제조 방법 |
-
2012
- 2012-03-26 KR KR1020120030540A patent/KR101240518B1/ko active IP Right Grant
-
2013
- 2013-03-21 JP JP2013058334A patent/JP5934132B2/ja not_active Expired - Fee Related
- 2013-03-22 US US13/848,841 patent/US8822551B2/en active Active
- 2013-03-26 EP EP13161184.0A patent/EP2644623B1/en not_active Not-in-force
- 2013-03-26 CN CN201310100920.6A patent/CN103360633B/zh not_active Expired - Fee Related
- 2013-03-26 ES ES13161184.0T patent/ES2621280T3/es active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07102002A (ja) * | 1993-09-30 | 1995-04-18 | Gunze Ltd | 架橋ヒアルロン酸及びこれらの複合材料 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102093660B1 (ko) * | 2019-07-08 | 2020-03-26 | (주)리젠바이오참 | 온도감응형 조직유착 방지용 하이드로겔 조성물 및 그 제조방법 |
WO2021040493A1 (ko) * | 2019-07-08 | 2021-03-04 | (주)리젠바이오참 | 온도감응형 조직유착 방지용 하이드로겔 조성물 및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
ES2621280T3 (es) | 2017-07-03 |
EP2644623B1 (en) | 2017-03-08 |
CN103360633A (zh) | 2013-10-23 |
KR101240518B1 (ko) | 2013-03-11 |
CN103360633B (zh) | 2015-07-22 |
US20130253074A1 (en) | 2013-09-26 |
JP5934132B2 (ja) | 2016-06-15 |
EP2644623A1 (en) | 2013-10-02 |
US8822551B2 (en) | 2014-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5934132B2 (ja) | 生体適合性高分子を用いた移植用材料 | |
JP6250591B2 (ja) | 組織ドレッシングキット | |
KR102071029B1 (ko) | 생체안정성과 기계적 물성이 향상된 생분해성 고분자 하이드로겔 복합체 및 이의 제조방법 | |
Li et al. | Antibacterial, hemostasis, adhesive, self-healing polysaccharides-based composite hydrogel wound dressing for the prevention and treatment of postoperative adhesion | |
CN1181980A (zh) | 来自氧化多糖类的可生物吸收的医用品 | |
Mayes et al. | Polysaccharide-based films for the prevention of unwanted postoperative adhesions at biological interfaces | |
KR101607849B1 (ko) | 생분해성 고분자 필름 및 그 제조방법 | |
KR101678402B1 (ko) | 창상치료용 알긴산 하이드로젤 및 그 제조방법 | |
KR20130123080A (ko) | 히알루론산 에폭사이드 가교체 및 그 제조방법 | |
WO2020226587A1 (en) | A biocompatible, biodegradable and bioresorbable adhesion membrane including hyaluronic acid / chitosan / carboxymethyl cellulose and production method | |
KR101413510B1 (ko) | 생체 적합성 고분자를 이용한 이식용 재료의 제조방법 | |
KR101180286B1 (ko) | 히알루론산 에폭사이드 유도체 하이드로겔을 포함하는 유착방지제 및 이의 제조 방법 | |
CN115569232A (zh) | 双层水凝胶敷料及其制备方法和应用 | |
Ribeiro et al. | Cellulose-based hydrogels in topical drug delivery: A challenge in medical devices | |
KR20170029817A (ko) | 간격체 함유한 생체적합성 조성물 및 그의 제조방법 | |
AU2021312621A1 (en) | Anti-adhesion polymer composition | |
KR101443673B1 (ko) | 히알루론산 유도체 스펀지의 제조방법 및 그에 의하여 제조된 히알루론산 유도체 스펀지 | |
EP3263141A1 (en) | Medical material and anti-adhesion material | |
CN113150323B (zh) | N-(2-羟丙基)甲基丙烯酰胺透明质酸水凝胶、制备方法及应用 | |
Guo et al. | Preparation of antiadhesion polypropylene mesh using bacterial cellulose combined with chitosan hydrogel application in rat abdominal incisional hernia | |
KR20170012867A (ko) | 입자형 무세포 진피 기반의 온도감응성 유착방지 조성물의 제조방법 | |
JP2010035744A (ja) | 癒着防止材 | |
EP2146755B1 (en) | Device made at least partially of n-acetylchitosan with controlled biodissolution | |
JP2003019194A (ja) | ヒアルロン酸とカルボキシメチルセルロースからなる共架橋ゲル組成物 | |
KR20190085249A (ko) | 히알루론산-젤라틴 중합체를 포함하는 유착방지용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130711 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131011 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131126 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140326 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140502 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140513 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151013 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160125 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160506 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5934132 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |